<p>MiMedx Group, Inc（纳斯达克代码：MDXG - 免费报告）- 北方证券的投资分析师在 4 月 17 日星期五发布的研究报告中下调了 MiMedx Group 2026 年第三季度每股收益（EPS）预期。北方证券分析师 C. Byrnes 现在预计该公司本季度每股收益为$0.00，低于之前预测的$0.03。MiMedx Group 当前全年的每股收益共识预期为$0.30。北方证券还对 MiMedx Group 2026 年第四季度的每股收益预期为$0.01。</p>
<p>MiMedx Group（纳斯达克代码：MDXG - 获取免费报告）最近一次发布财报是在 2 月 25 日星期三。该公司报告本季度每股收益为$0.14，超出分析师共识预期的$0.09，超出幅度为$0.05。该公司本季度的收入为 1.181 亿美元，而分析师预期为 1.0678 亿美元。MiMedx Group 的净利润率为 11.60%，股本回报率为 29.37%。</p>
<p>其他一些分析师也对 MDXG 发表了看法。花旗集团在 2 月 23 日星期一的研究报告中开始覆盖 MiMedx Group 的股票，并给予该公司 “市场表现优于大盘” 的评级。Weiss Ratings 在 12 月 29 日星期一的研究报告中重申了对 MiMedx Group 股票的 “持有（c）” 评级。华尔街 Zen 在 2 月 28 日星期六的研究报告中将 MiMedx Group 的股票评级从 “强力买入” 下调至 “买入”。瑞银集团在 2 月 23 日星期一的研究报告中设定了 MiMedx Group 股票的目标价为$10.00。最后，Lake Street Capital 在 1 月 20 日星期二的研究报告中将 MiMedx Group 股票的目标价从$12.00 下调至$10.00，并给予该公司 “买入” 评级。六位分析师对该股票给予了买入评级，一位分析师对该公司的股票给予了持有评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，共识目标价为$9.17。</p>
<p><strong>阅读我们关于 MiMedx Group 的最新报告</strong></p>
<h2>MiMedx Group 股价下跌 0.3%</h2>
<p>MiMedx Group 的股票在周一开盘价为$3.41。该公司的速动比率为 3.92，流动比率为 4.32，债务与股本比率为 0.06。该公司的 50 日移动平均价格为$4.46，200 日移动平均价格为$5.85。该公司的市值为 5.0662 亿美元，市盈率为 10.66，贝塔值为 1.65。MiMedx Group 的 52 周低点为$3.31，52 周高点为$7.99。</p>
<h2>MiMedx Group 的机构交易</h2>
<p>几家机构投资者和对冲基金最近增加或减少了对 MDXG 的持股。SG Americas Securities LLC 在第一季度将其在 MiMedx Group 的持股增加了 28.6%。SG Americas Securities LLC 目前拥有 241,881 股该公司的股票，价值$955,000，在此期间又增持了 53,836 股。World Investment Advisors 在第四季度新购入了 MiMedx Group 的股份，价值约为$173,000。Virtu Financial LLC 在第四季度新购入了 MiMedx Group 的股份，价值约为$78,000。Invesco Ltd.在第四季度将其在 MiMedx Group 的持股增加了 5.9%。Invesco Ltd.目前拥有 84,824 股该公司的股票，价值$574,000，在此期间又增持了 4,708 股。最后，Corient Private Wealth LLC 在第四季度将其在 MiMedx Group 的持股增加了 26.0%。Corient Private Wealth LLC 目前拥有 46,658 股该公司的股票，价值$316,000，在此期间又增持了 9,614 股。79.15% 的股票由机构投资者和对冲基金持有。</p>
<h2>MiMedx Group 公司简介</h2>
<p>（获取免费报告）</p>
<p>MiMedx Group, Inc 是一家生物制药公司，专注于开发、制造和营销源自人类胎盘组织的再生生物材料产品。该公司的核心使命是利用羊膜和绒毛膜中的细胞外基质和生长因子来支持伤口愈合和外科应用。MiMedx 的产品线利用专有的净化工艺，旨在保留原生组织特性，同时确保无菌和安全。</p>
<p>MiMedx 的主要产品包括以 EpiFix®和 AmnioFix®等品牌命名的羊膜/绒毛膜同种异体移植物，适用于急性和慢性伤口的治疗，包括糖尿病足溃疡、静脉性腿部溃疡和手术部位修复。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比 MiMedx Group 更具投资价值</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURYRw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURYRw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 MiMedx Group 吗？</h2>
<p>在考虑 MiMedx Group 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 MiMedx Group 并不在名单上。</p>
<p>虽然 MiMedx Group 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得投资。</p>
<p>查看这五只股票</p>

MDXG

<p>北方证券的投资分析师已将 MiMedx Group（纳斯达克代码：MDXG）2026 年第三季度每股收益（EPS）预估从 0.03 美元下调至 0.00 美元。市场共识对该公司全年收益的预估为每股 0.30 美元。MiMedx Group 最近报告的第四季度每股收益为 0.14 美元，超出预期。目前该股票的评级为 “适度买入”，目标价格为 9.17 美元。MiMedx Group 专注于从人类胎盘组织中提取的再生生物材料产品，主要用于伤口愈合和外科应用</p>

<p>MiMedx Group, Inc (NASDAQ:MDXG - Free Report) - Investment analysts at Northland Securities lowered their Q3 2026 EPS estimates for shares of MiMedx Group in a research note issued on Friday, April 17th. Northland Securities analyst C. Byrnes now anticipates that the company will post earnings per share of $0.00 for the quarter, down from their previous forecast of $0.03. The consensus estimate for MiMedx Group's current full-year earnings is $0.30 per share. Northland Securities also issued estimates for MiMedx Group's Q4 2026 earnings at $0.01 EPS.</p>
<div class="lb-trans"><p>MiMedx Group, Inc（纳斯达克代码：MDXG - 免费报告）- 北方证券的投资分析师在 4 月 17 日星期五发布的研究报告中下调了 MiMedx Group 2026 年第三季度每股收益（EPS）预期。北方证券分析师 C. Byrnes 现在预计该公司本季度每股收益为$0.00，低于之前预测的$0.03。MiMedx Group 当前全年的每股收益共识预期为$0.30。北方证券还对 MiMedx Group 2026 年第四季度的每股收益预期为$0.01。</p>
</div><p>MiMedx Group (NASDAQ:MDXG - Get Free Report) last posted its earnings results on Wednesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.09 by $0.05. The firm had revenue of $118.10 million during the quarter, compared to analyst estimates of $106.78 million. MiMedx Group had a net margin of 11.60% and a return on equity of 29.37%.</p>
<div class="lb-trans"><p>MiMedx Group（纳斯达克代码：MDXG - 获取免费报告）最近一次发布财报是在 2 月 25 日星期三。该公司报告本季度每股收益为$0.14，超出分析师共识预期的$0.09，超出幅度为$0.05。该公司本季度的收入为 1.181 亿美元，而分析师预期为 1.0678 亿美元。MiMedx Group 的净利润率为 11.60%，股本回报率为 29.37%。</p>
</div><p>A number of other analysts have also weighed in on MDXG. Citigroup started coverage on shares of MiMedx Group in a research note on Monday, February 23rd. They issued a &#34;market outperform&#34; rating for the company. Weiss Ratings reaffirmed a &#34;hold (c)&#34; rating on shares of MiMedx Group in a research note on Monday, December 29th. Wall Street Zen lowered shares of MiMedx Group from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research note on Saturday, February 28th. UBS Group set a $10.00 price target on shares of MiMedx Group in a research note on Monday, February 23rd. Finally, Lake Street Capital reduced their price target on shares of MiMedx Group from $12.00 to $10.00 and set a &#34;buy&#34; rating for the company in a research note on Tuesday, January 20th. Six analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $9.17.</p>
<div class="lb-trans"><p>其他一些分析师也对 MDXG 发表了看法。花旗集团在 2 月 23 日星期一的研究报告中开始覆盖 MiMedx Group 的股票，并给予该公司 “市场表现优于大盘” 的评级。Weiss Ratings 在 12 月 29 日星期一的研究报告中重申了对 MiMedx Group 股票的 “持有（c）” 评级。华尔街 Zen 在 2 月 28 日星期六的研究报告中将 MiMedx Group 的股票评级从 “强力买入” 下调至 “买入”。瑞银集团在 2 月 23 日星期一的研究报告中设定了 MiMedx Group 股票的目标价为$10.00。最后，Lake Street Capital 在 1 月 20 日星期二的研究报告中将 MiMedx Group 股票的目标价从$12.00 下调至$10.00，并给予该公司 “买入” 评级。六位分析师对该股票给予了买入评级，一位分析师对该公司的股票给予了持有评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，共识目标价为$9.17。</p>
</div><p><strong>Read Our Latest Report on MiMedx Group</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 MiMedx Group 的最新报告</strong></p>
</div><h2>MiMedx Group Trading Down 0.3%</h2>
<div class="lb-trans"><h2>MiMedx Group 股价下跌 0.3%</h2>
</div><p>MiMedx Group stock opened at $3.41 on Monday. The company has a quick ratio of 3.92, a current ratio of 4.32 and a debt-to-equity ratio of 0.06. The firm has a 50-day moving average price of $4.46 and a two-hundred day moving average price of $5.85. The firm has a market capitalization of $506.62 million, a price-to-earnings ratio of 10.66 and a beta of 1.65. MiMedx Group has a 52-week low of $3.31 and a 52-week high of $7.99.</p>
<div class="lb-trans"><p>MiMedx Group 的股票在周一开盘价为$3.41。该公司的速动比率为 3.92，流动比率为 4.32，债务与股本比率为 0.06。该公司的 50 日移动平均价格为$4.46，200 日移动平均价格为$5.85。该公司的市值为 5.0662 亿美元，市盈率为 10.66，贝塔值为 1.65。MiMedx Group 的 52 周低点为$3.31，52 周高点为$7.99。</p>
</div><h2>Institutional Trading of MiMedx Group</h2>
<div class="lb-trans"><h2>MiMedx Group 的机构交易</h2>
</div><p>Several institutional investors and hedge funds have recently added to or reduced their stakes in MDXG. SG Americas Securities LLC raised its holdings in shares of MiMedx Group by 28.6% during the first quarter. SG Americas Securities LLC now owns 241,881 shares of the company's stock valued at $955,000 after acquiring an additional 53,836 shares during the period. World Investment Advisors acquired a new stake in shares of MiMedx Group during the fourth quarter valued at approximately $173,000. Virtu Financial LLC acquired a new stake in shares of MiMedx Group during the fourth quarter valued at approximately $78,000. Invesco Ltd. raised its holdings in shares of MiMedx Group by 5.9% during the fourth quarter. Invesco Ltd. now owns 84,824 shares of the company's stock valued at $574,000 after acquiring an additional 4,708 shares during the period. Finally, Corient Private Wealth LLC increased its stake in MiMedx Group by 26.0% in the 4th quarter. Corient Private Wealth LLC now owns 46,658 shares of the company's stock valued at $316,000 after buying an additional 9,614 shares during the period. 79.15% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近增加或减少了对 MDXG 的持股。SG Americas Securities LLC 在第一季度将其在 MiMedx Group 的持股增加了 28.6%。SG Americas Securities LLC 目前拥有 241,881 股该公司的股票，价值$955,000，在此期间又增持了 53,836 股。World Investment Advisors 在第四季度新购入了 MiMedx Group 的股份，价值约为$173,000。Virtu Financial LLC 在第四季度新购入了 MiMedx Group 的股份，价值约为$78,000。Invesco Ltd.在第四季度将其在 MiMedx Group 的持股增加了 5.9%。Invesco Ltd.目前拥有 84,824 股该公司的股票，价值$574,000，在此期间又增持了 4,708 股。最后，Corient Private Wealth LLC 在第四季度将其在 MiMedx Group 的持股增加了 26.0%。Corient Private Wealth LLC 目前拥有 46,658 股该公司的股票，价值$316,000，在此期间又增持了 9,614 股。79.15% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>MiMedx Group Company Profile</h2>
<div class="lb-trans"><h2>MiMedx Group 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company's core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx's product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.</p>
<div class="lb-trans"><p>MiMedx Group, Inc 是一家生物制药公司，专注于开发、制造和营销源自人类胎盘组织的再生生物材料产品。该公司的核心使命是利用羊膜和绒毛膜中的细胞外基质和生长因子来支持伤口愈合和外科应用。MiMedx 的产品线利用专有的净化工艺，旨在保留原生组织特性，同时确保无菌和安全。</p>
</div><p>MiMedx's principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.</p>
<div class="lb-trans"><p>MiMedx 的主要产品包括以 EpiFix®和 AmnioFix®等品牌命名的羊膜/绒毛膜同种异体移植物，适用于急性和慢性伤口的治疗，包括糖尿病足溃疡、静脉性腿部溃疡和手术部位修复。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than MiMedx Group</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 MiMedx Group 更具投资价值</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURYRw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=MDXG"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in MiMedx Group Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 MiMedx Group 吗？</h2>
</div><p>Before you consider MiMedx Group, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 MiMedx Group 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiMedx Group wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 MiMedx Group 并不在名单上。</p>
</div><p>While MiMedx Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 MiMedx Group 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得投资。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

MiMedx 集团第三季度每股收益预期被 Northland Securities 下调